Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. Show more

Location: 11250 El Camino Real, San Diego, CA, 92130, United States | Website: https://skyebioscience.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

44.26M

52 Wk Range

$1.14 - $5.75

Previous Close

$1.37

Open

$1.33

Volume

227,289

Day Range

$1.28 - $1.40

Enterprise Value

6.364M

Cash

35.31M

Avg Qtr Burn

-10.37M

Insider Ownership

1.39%

Institutional Own.

62.97%

Qtr Updated

09/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nimacimab Details Obesity	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nimacimab Details Metabolic-associated steatotic liver disease (MASLD)	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.